GLP-1s' Secret: They Aren't Actually Weight Loss Drugs
GLP-1 medications are usually talked about as weight loss shots. That is understandable — weight loss is the part people see first. But the more useful conversation is bigger than appetite. These medications work through hormone signaling, and that signal touches several systems at once: blood sugar, digestion, hunger, inflammation, blood vessels, and in some cases heart, kidney, and sleep-related outcomes.
Quick answer: what do GLP-1 medications actually do?
GLP-1 medications mimic or enhance a natural hormone signal involved in appetite, insulin release, digestion speed, and blood sugar regulation. Drugs in this category — including semaglutide and tirzepatide — have also been studied for cardiovascular risk, kidney outcomes, and obstructive sleep apnea in certain patient groups.
GLP-1 is a hormone signal, not just an appetite switch
GLP-1 stands for glucagon-like peptide-1. Your body makes it naturally, mainly in response to eating. It helps release insulin when glucose is elevated, reduces glucagon signaling, slows gastric emptying, signals fullness in the brain, and influences metabolic and vascular pathways. People often notice the appetite change first and assume the medication is only an appetite suppressant — that misses part of the biology.
What weakens your natural GLP-1 signal
Three common reasons the signal can be too weak or too noisy: ultra-processed food, chronic inflammation, and insulin resistance. Whole-food meals built around protein and fiber send the body more useful information than highly processed snacks and liquid calories. Poor sleep, ongoing stress, visceral fat, and low activity can keep the body in a low-grade stress state. For more on the visceral fat piece, read What Visceral Fat Is Really Doing to You.
Why muscle loss is a real issue — but not a reason to panic
Any meaningful weight loss can include some lean mass loss. The risk gets worse when someone eats too little protein, stops moving, loses weight too quickly, or uses the medication as a substitute for a plan. The fix is not complicated: protein, resistance training, and tracking more than the scale.
What the research says beyond weight loss
The SELECT trial showed semaglutide reduced major adverse cardiovascular events in more than 17,000 adults with overweight or obesity and established cardiovascular disease. The FLOW trial found lower risk of important kidney outcomes, major cardiovascular events, and death in semaglutide-treated patients with type 2 diabetes and chronic kidney disease. In December 2024, the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity.
What this means for someone considering GLP-1 support
The better question is whether a GLP-1 is appropriate for your body, labs, history, goals, and the way you are willing to follow through. Some people need medical weight loss options. Some need labs first. Some need to protect muscle before chasing the next lower number on the scale. If you are in Rapid City or the Black Hills, start with a clear evaluation before choosing a path.
Book a free 15-minute call with Mike →